Inscription Capital LLC Buys New Stake in Alumis Inc. $ALMS

Inscription Capital LLC purchased a new stake in Alumis Inc. (NASDAQ:ALMS) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 20,434 shares of the company’s stock, valued at approximately $82,000.

A number of other institutional investors also recently bought and sold shares of the business. Stonepine Capital Management LLC acquired a new stake in shares of Alumis during the 2nd quarter worth about $1,049,000. Trium Capital LLP increased its stake in Alumis by 17.9% in the third quarter. Trium Capital LLP now owns 3,122,111 shares of the company’s stock valued at $12,457,000 after purchasing an additional 474,072 shares during the last quarter. General Atlantic L.P. acquired a new stake in Alumis during the second quarter worth approximately $3,893,000. Velan Capital Investment Management LP acquired a new stake in Alumis during the second quarter worth approximately $4,863,000. Finally, Los Angeles Capital Management LLC acquired a new position in shares of Alumis in the 2nd quarter valued at $368,000.

Analyst Ratings Changes

A number of research analysts recently commented on ALMS shares. Loop Capital set a $37.00 target price on shares of Alumis in a research report on Wednesday. UBS Group reiterated an “outperform” rating on shares of Alumis in a research report on Tuesday, January 6th. Wall Street Zen raised Alumis from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. Chardan Capital started coverage on Alumis in a research note on Wednesday. They set a “buy” rating and a $37.00 price target on the stock. Finally, Wells Fargo & Company lifted their price target on Alumis from $17.00 to $39.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 6th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $37.50.

Insider Buying and Selling

In related news, Director Srinivas Akkaraju purchased 588,235 shares of the firm’s stock in a transaction that occurred on Friday, January 9th. The stock was purchased at an average cost of $17.00 per share, with a total value of $9,999,995.00. Following the completion of the acquisition, the director directly owned 1,853,488 shares in the company, valued at $31,509,296. This trade represents a 46.49% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Foresite Capital Management Vi acquired 411,764 shares of the stock in a transaction that occurred on Thursday, January 8th. The stock was purchased at an average price of $17.00 per share, for a total transaction of $6,999,988.00. Following the completion of the transaction, the insider owned 5,702,536 shares in the company, valued at $96,943,112. The trade was a 7.78% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 4,612,402 shares of company stock worth $49,352,316 over the last three months. 40.70% of the stock is owned by company insiders.

Alumis Stock Down 6.7%

NASDAQ ALMS opened at $24.52 on Friday. The firm has a market cap of $2.56 billion, a P/E ratio of -6.05 and a beta of -2.09. Alumis Inc. has a 52-week low of $2.76 and a 52-week high of $27.20. The business’s 50-day moving average price is $13.08 and its 200 day moving average price is $7.41.

Alumis (NASDAQ:ALMS) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.14). The business had revenue of $2.07 million during the quarter, compared to analysts’ expectations of $3.14 million. As a group, analysts anticipate that Alumis Inc. will post -8.51 earnings per share for the current year.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.